|Articles|February 9, 2016

First MERS Autopsy Reveals the Virus' Organ Target

The findings differed from those in animal models, bringing to light new information on the virus.

Of the 1,500 patients who have been diagnosed with the Middle East Respiratory Syndrome (MERS), around one-third of them of died from the illness. The first autopsy report from one of those people has finally become available.

MERS-CoV first appeared in humans in 2012 after a patient was diagnosed in Saudi Arabia. Since then, the viral respiratory illness has made its way to several countries, including the United States. Unfortunately, a significant amount of patients succumb to the condition.

The first autopsy comes from a 45-year-old male who quickly went from symptoms of a fever, runny nose, and cough to death between April 2 and April 10, 2014. He worked in the storage room at a paramedic station and did not care for patients or have exposure to camels (a suspected transmission route). The patient was treated at a hospital in the United Arab Emirates and was given 100 mg of the steroid hydrocortisone every eight hours on his last day. The autopsy was performed 10 days after his death and it has been described in The American Journal of Pathology.

MERS-CoV is new to humans and as such, researchers do not exactly know how the virus infects patients. Individuals at an increased risk of sickness include those who travel to the Arabian Peninsula, are exposed to camels, and are in close contact with someone with confirmed MERS-CoV.

Often times, patients with MERS-CoV show signs of acute kidney failure. The autopsy results, however, did not show evidence of the virus in the patient’s kidneys.

“This suggests that the acute renal failure in this patient was not caused by direct renal infection, but likely by other factors such as hypotension,” lead investigator Sherif R. Zaki, MD, PhD, chief of the Infectious Diseases Pathology Branch at the Centers for Disease Control and Prevention in Atlanta, said in a news release.

It appears that MERS-CoV’s main organ target were the lungs. The researchers found anti-MERS-CoV antibodies in the pneumocytes and epithelial syncytial cells in the lungs, as well as in the bronchial submucosal glands.

“Infection of bronchial submucosal glands is a likely source of viral shedding in respiratory secretions leading to human-to-human transmission,” Zaki explained. The findings differed from those found in animal models, which shows the importance of human pathology.

David H. Walker, MD, director of the University of Texas Medical Branch (Galveston) Center for Biodefense and Emerging Infectious Diseases, says that the long interval between first diagnosis and first autopsy was a missed opportunity. It has been noted, however, that autopsies in the United States have dropped significantly over the past few years. Insight on MERS-CoV was gained through multiple animal models, but obviously, animal models do not have all of the same features as humans.

“Until the truth-testing of a large series of autopsies is reported, judgment will favor those models supported by the observations in a single postmortem examination,” said Walker, who was not affiliated with the study.

The takeaway on this new research is that although this autopsy provides great insight into MERS-CoV, more than one autopsy is needed to fully understand its pathology.


Related to this article

Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Measles Update: October 16, 2026
The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state's massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal.
NFID Survey Finds Respiratory Vaccine Gap Driven by Lack of Clarity, Not Hesitancy
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.